Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Eeden converts end-of-life textiles into resources for new textile production.
Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
AIRNA develops RNA editing technologies to create medicines for various diseases.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.
Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Navigator Medicines operate as a biotech company.
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Seamless Therapeutics is reshaping the gene editing paradigm with a novel approach to restoring health in patients.
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Calluna Pharma is developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.
Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Forbion Capital Partners has invested in 122 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 16 different industry categories.
Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post Ipo Equity round. Forbion Capital Partners's total known invested capital is $9.0B.
Forbion Capital Partners's average investment size is $95.7M across its portfolio of 122 companies.
Recent Forbion Capital Partners portfolio additions include Expedition Therapeutics, Mosanna Therapeutics, Azafaros, Eeden, Granite Bio. These companies were founded in 2020 or later.